文献速递耳科与耳神经小儿耳鼻咽喉

更昔洛韦与槲皮素-P188联合治疗能否改善巨细胞病毒诱导的听力损失

Can Ganciclovir and Quercetin-P188 Ameliorate Cytomegalovirus Induced Hearing Loss?
PubMed 文献 · Laryngoscope · 2023-08-17

研究采用小鼠巨细胞病毒(CMV)模型,比较更昔洛韦(GCV)、槲皮素-P188(QP188)、GCV+QP188联合及P188载体腹腔注射14天的听力学与病毒载量变化。结果显示联合治疗组在4、6、8周龄时ABR和DPOAE阈值显著低于各单药及载体组,病毒滴度较P188单药组呈非显著降低。结论认为联合治疗有效改善CMV诱导的感音神经性听力损失,部分或与病毒滴度降低相关。

要点

  • GCV+QP188联合治疗组在4、6、8周龄时ABR阈值和DPOAE阈值均显著低于GCV单药、QP188单药及P188载体组(p<0.001)。
  • GCV+QP188联合、GCV单药、QP188单药三组平均病毒滴度较P188单药组呈非显著降低(p=0.08)。
  • 结论认为联合治疗有效改善小鼠CMV诱导的感音神经性听力损失,部分或与颞骨病毒滴度降低相关。

核心结论

  • 在小鼠模型中,GCV与辅料槲皮素及P188联合治疗有效改善了CMV诱导的感音神经性听力损失。
  • 该结果部分或可由小鼠颞骨病毒滴度降低解释,并与体外细胞培养显示加性抗病毒效应的研究相关。

研究设计与样本

  • 研究采用BALB/c小鼠巨细胞病毒模型,于出生后第3天(p3)感染小鼠CMV。
  • 治疗组分别接受GCV、QP188、GCV+QP188或P188递送载体,每12小时腹腔注射一次,自p3起连续治疗14天。
  • 未感染对照组接受联合方案、生理盐水或P188递送载体。
  • 于4、6、8周龄时用畸变产物耳声发射(DPOAE)和听性脑干反应(ABR)评估听阈。
  • 另取CMV感染组于p10采集颞骨,用定量聚合酶链反应测定病毒载量。

主要发现

  • GCV+QP188联合治疗组在4、6、8周龄时ABR阈值(p<0.001)和DPOAE阈值(p<0.001)均显著低于GCV单药组、QP188单药组和P188递送载体组。
  • GCV+QP188联合治疗、GCV单药和QP188单药三组平均病毒滴度较P188单药组呈非显著降低(p=0.08)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Determine whether combination therapy with ganciclovir (GCV) and a Quercetin-P188 solution improves hearing outcomes in a murine cytomegalovirus (CMV) model. METHODS: BALB/c mice were infected with murine CMV on postnatal day 3 (p3). Quercetin was solubilized in saline using P188 (QP188). Treatment groups received either GCV, QP188, GCV and QP188, or P188 delivery vehicle BID at 12-hour intervals via intraperitoneal injection. All treatment groups were treated for 14 days starting at p3. Uninfected controls were treated with the combined regimen, saline or P188 delivery vehicle. Auditory thresholds were assessed using distortion product otoacoustic emission (DPOAE) and auditory brainstem response (ABR) testing at 4, 6, and 8 weeks of age. Temporal bones from separate CMV-infected groups were harvested at p10, and viral load was determined by quantitative polymerase chain reaction. RESULTS: CMV-infected mice receiving combination therapy GCV+QP188 demonstrated statistically significant lower ABR (p < 0.001) and DPOAE thresholds (p < 0.001) compared with mice treated with GCV monotherapy, QP188 monotherapy, and P188 delivery vehicle at 4, 6, and 8 weeks of age. GCV+QP188 combination therapy, GCV monotherapy, and QP188 monotherapy resulted in a nonsignificant reduction in mean viral titers compared to P188 monotherapy (p = 0.08). CONCLUSION: Combining GCV with the excipients quercetin and P188 effectively ameliorated CMV-induced sensorineural hearing loss in a murine model. This result may be partially explained by a reduction in viral titers in mouse temporal bones that correlate with in vitro studies demonstrating additive antiviral effect in cell culture. LEVEL OF EVIDENCE: NA Laryngoscope, 134:1457-1463, 2024.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Suarez D, Kjar A, Scott B, et al. Can Ganciclovir and Quercetin-P188 Ameliorate Cytomegalovirus Induced Hearing Loss? Laryngoscope. 2023. PMID: 37589298. doi:10.1002/lary.30975

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。